Home - Clinical Trials Arena
Testosterone can predict cardiometabolic disease in men with erectile dysfunction. The study, from the Kaohsiung Armed Forces General Hospital in Taiwan, contained 3,909 men with ED between 2010 and 2021.
Most significant clinical trials of 2024
2024年12月23日 · Most significant clinical trials of 2024. From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.
Sectors - Clinical Trials Arena
Sections. Company A-Z; Company Categories; Products & Services; Company Releases; White Papers; Videos; Buyer's Guides; Partner Content; Latest. Leading Sales Enablement, Prospecting and Automation Providers and Technology Solutions for the Clinical Trials Industry
About Us Online - Clinical Trials Arena
Clinicaltrialsarena.com covers every aspect of the drug development and research process, from conception to pre-FDA approval.. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone – from senior management through to research and QA staff – …
Clinical Trials - Clinical Trials Arena
German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial. Initial efficacy outcomes from cohort 5 are anticipated in the second half of this year.
AHA 2024: Zerlasiran shows promising Phase II results for elevated ...
2024年11月19日 · Dr. Steven Nissen, MD chairman and chief academic officer of the Heart and Vascular Institute at the Cleveland Clinic and professor of medicine at the Lerner College of Medicine, reported that subcutaneous injections of 300mg or 450mg of zerlasiran, administered every 16 or 24 weeks, reduced time-averaged Lp(a) levels by 80% to 85% over a follow-up period of 36 to 60 weeks.
Genprex doses first subject in expansion part of Acclaim-3 trial
2 天之前 · Enrolment for this interim analysis is anticipated to conclude in the second half of this year. Genprex chief medical officer Mark Berger said: “We are excited to begin the Phase II expansion portion of Acclaim-3, which will determine the 18-week progression-free survival (PFS) rate of REQORSA and Tecentriq combination maintenance therapy.
Rakuten doses first patients in multi-continental Phase III HNSCC …
1 天前 · Known as the ASP-1929-381 trial (NCT06699212), it is specifically looking to examine locoregional recurrent HNSCC without distant metastases. Credit: Shutterstock / Photoroyalty Rakuten Medical has dosed the first patient in its intercontinental Phase III trial into its photoimmunotherapy, ASP-1929 ...
Pipeline Moves: Moderna’s pandemic influenza vaccine trial …
2024年8月19日 · This week on Pipeline Moves, we kick off by looking at a Phase I/II trial completion by Moderna of its pandemic influenza vaccine off the back of a government grant.. Meanwhile, an investigator-led trial of BMS’s ricolinostat has been terminated In non-Hodgkin lymphoma and Hodgkin lymphoma and F-star Therapeutics terminated a trial of FS-118 due to a business decision.
Market Data - Clinical Trials Arena
Japan accounts for 4.7% share of global clinical trial activity in 2022. Japan has accounted for a 4.7% share of the global clinical trials activity in 2022, registering a decrease when compared…